Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

At AstraZeneca our industry-leading pipeline includes investigational therapies in various stages of clinical development - from approved medicines to earlier-stage molecules in clinical trials.

AstraZeneca-sponsored or -directed trial New Molecular Entities (NMEs) and significant indications First major market regulatory submission date and submission status is provided for assets in Phase III or beyond.

17 – Pipeline: Oncology • An effective immune response is durable - possibly life-long • Cancer hijacks many immune pathways to escape destruction • Our robust pipeline allows identification of combinations that restore the immune response

By combining pioneering science, digital technologies, big data and AI with the skills and experience of talented people, our pipeline goes beyond traditional small molecules, monoclonal antibodies and peptides, to include nucleotide modalities such as antisense oligonucleotides.

Apr 14, 2023 · AstraZeneca will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research (AACR) Annual Meeting, 14 to 19 April 2023.

1. AstraZeneca. Vaxzevria shown in expert review to provide equally effective protection against COVID-19 hospitalisation and death as mRNA vaccines [Last accessed: October 2022]. Available from: https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19 ...

An exciting pipeline. Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Nov 7, 2024 · AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in haematology at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition 7 to 10 December 2024.

AstraZeneca Development Pipeline as at 10 February 2022 References to Notes and page numbers, and capitalised terms not defined in this supplement can be found in AstraZeneca’s Annual Report and Form 20-F Information 2021 at www.astrazeneca.com/annualreport2021.